Tselis A - Search Results

1

Glatiramer acetate therapy for multiple sclerosis: a review.

Perumal J, Filippi M, Ford C, Johnson K, Lisak R, Metz L, Tselis A, Tullman M, Khan O. Perumal J, et al. Among authors: tselis a. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):1019-29. doi: 10.1517/17425255.2.6.1019. Expert Opin Drug Metab Toxicol. 2006. PMID: 17125414 Review.

2

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Khan O, et al. Among authors: tselis a. CNS Drugs. 2002;16(8):563-78. doi: 10.2165/00023210-200216080-00005. CNS Drugs. 2002. PMID: 12096936 Review.

3

Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.

Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R. Khan O, et al. Among authors: tselis a. Mult Scler. 2005 Dec;11(6):646-51. doi: 10.1191/1352458505ms1234oa. Mult Scler. 2005. PMID: 16320723 Clinical Trial.

4

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.

Khan O, Shen Y, Bao F, Caon C, Tselis A, Latif Z, Zak I. Khan O, et al. Among authors: tselis a. J Neuroimaging. 2008 Jul;18(3):314-9. doi: 10.1111/j.1552-6569.2007.00206.x. J Neuroimaging. 2008. PMID: 18304034

5

Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy.

Zvartau-Hind M, Caon C, Zabad R, Tselis A, Lisak R, Khan O. Zvartau-Hind M, et al. Among authors: tselis a. Expert Rev Neurother. 2002 May;2(3):285-94. doi: 10.1586/14737175.2.3.285. Expert Rev Neurother. 2002. PMID: 19810859

6

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Caon C, et al. Among authors: tselis a. Eur J Neurol. 2006 May;13(5):471-4. doi: 10.1111/j.1468-1331.2006.01273.x. Eur J Neurol. 2006. PMID: 16722971 Clinical Trial.

7

Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.

Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O. Perumal JS, et al. Among authors: tselis a. Eur J Neurol. 2008 Jul;15(7):677-80. doi: 10.1111/j.1468-1331.2008.02146.x. Epub 2008 May 6. Eur J Neurol. 2008. PMID: 18459972

8

Multiple sclerosis: therapeutic update.

Tselis AC, Lisak RP. Tselis AC, et al. Arch Neurol. 1999 Mar;56(3):277-80. doi: 10.1001/archneur.56.3.277. Arch Neurol. 1999. PMID: 10190816 Review.

9

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.

Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. Khan OA, et al. Among authors: tselis ac. Eur J Neurol. 2001 Mar;8(2):141-8. doi: 10.1046/j.1468-1331.2001.00189.x. Eur J Neurol. 2001. PMID: 11284992 Clinical Trial.

10

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.

Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. Khan OA, et al. Among authors: tselis ac. Mult Scler. 2001 Dec;7(6):349-53. doi: 10.1177/135245850100700601. Mult Scler. 2001. PMID: 11795454 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page